Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update
about
MinION: A Novel Tool for Predicting Drug Hypersensitivity?Pharmacogenomics in the clinicImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsPharmacogenetics and Predictive Testing of Drug Hypersensitivity ReactionsChallenges to integrating pharmacogenetic testing into medication therapy managementPharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next DecadeElectronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.Pharmacogenomics of off-target adverse drug reactions.Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.Clinician Perspectives on Using Pharmacogenomics in Clinical Practice.Creating Shareable Clinical Decision Support Rules for a Pharmacogenomics Clinical Guideline Using Structured Knowledge Representation.Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)An update on the pharmacogenetics of treating hypertension.Genomic architecture of pharmacological efficacy and adverse events.Building the foundation for genomics in precision medicine.Clinical application of pharmacogenetics: focusing on practical issues.Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC).The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Integrating pharmacogenomics into electronic health records with clinical decision support.Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes.Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services.Editorial: Biomarkers in Drug Hypersensitivity.Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.Genome sequencing as a platform for pharmacogenetic genotyping: a pediatric cohort study.Comparison of genome sequencing and clinical genotyping for pharmacogenes.Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.Biomarkers of adverse drug reactions.PharmGKB: A worldwide resource for pharmacogenomic information.
P2860
Q26744637-EDAC6BD3-F183-43D1-B907-16D24A3E4668Q26782786-6B0223C1-0839-43B0-B37A-DB935DF25978Q26787099-2F4E107D-7AAF-451E-958A-AAEA1253EA35Q28066096-3C301929-AEF3-4461-B480-08F28930896BQ28082835-DF6D2E8C-C631-4CA3-8004-E26D94BBE8C7Q28392069-537FC363-3267-475C-BAE3-BEDE56EB3C3DQ30234897-E67F2E57-5680-4B18-826A-AB7CA0D4400BQ30400366-FE3292B7-B6FF-40DF-8733-A25634C42A33Q33725390-CE343E15-5FCF-4C8D-B5BB-783AC2337232Q33815409-4B760122-9397-471D-AD71-C8D92E897452Q36331666-B7352CB1-40B9-453F-838F-0680CE53CAB6Q36613405-58D0547F-E8AB-44EF-8C77-83CDA5B5AC85Q37433329-F9841849-C627-49C2-94C0-EEF4375A9B38Q37597647-90AE8436-F362-4BB0-98FE-6B0DA777BDCEQ38263731-DA0EF96A-7908-412C-97B1-08C258BA0B05Q38292930-5135AD71-86A1-47F7-AEED-7A58E6F31168Q38385958-E21E1731-A64D-4969-B3C3-7605AC47A65DQ38593942-4196F4BF-4DF3-4C2E-B6CC-A88656D89780Q38888585-ABC5AC4A-4BA5-4E71-AB45-F9D028CE60DDQ39123582-0B2B91B8-C7A3-406F-A66A-605B3B5AD1D8Q39173298-F717FD3D-E77C-489E-949F-EE4EC5DC1C2DQ39173300-9932576D-B838-4E9A-85B4-837024EC4DD5Q39496541-D7F9F104-5925-45D2-9DB0-061A07F29BD7Q42102584-B2B03FCE-124B-4A87-879A-AF21A7B32BBEQ42341755-CFA78A01-5A72-4483-8638-7B9945B57FAEQ46776696-1BBF21F9-E3D9-4055-B29C-A61367061675Q46979922-7B6AD6BD-743D-4449-B7AC-836177A4A822Q47128107-25A5B605-D374-4E76-B689-54B4B45A2E40Q47546923-B3C05544-8B22-4940-8DA5-968201F2D0A5Q47928481-8C08E09D-A1F5-4517-A1B7-9F65352A3955Q55442102-4E071F5B-578D-4824-BB58-6FEF9E89AB55
P2860
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@ast
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@en
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@nl
type
label
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@ast
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@en
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@nl
prefLabel
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@ast
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@en
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@nl
P2093
P2860
P3181
P356
P1476
Clinical Pharmacogenetics Impl ...... d Abacavir Dosing: 2014 update
@en
P2093
D L Kroetz
J M Hoffman
M A Martin
M R Wilkinson
R R Freimuth
P2860
P304
P3181
P356
10.1038/CLPT.2014.38
P407
P577
2014-05-01T00:00:00Z